


We Have an Innovative Pipeline Across our Therapeutic Areas



OD Orphan Drug Designation (in any region / indication for a given asset)

▶ Stage-ups/additions after Q2 FY18

▾ Stage-ups/additions since April 1, 2018

▴ Partnered asset

▫ Registration enabling study

▫ Assets shown in Phases 1-3 explicitly refer to new molecular entities

*With ongoing significant clinical development activities; Pipeline as of February 1, 2019

Maximizing the value of Life Cycle Management programs



	PHASE 1	PHASE 2	PHASE 3	FILED
ONCOLOGY	ALUNBRIG* ALK inhibitor 1L ALK+NSCLC (CN) NINLARO* Proteasome inhibitor ND MM (CN) NINLARO* Proteasome inhibitor Mnt ND MM post-SCT (CN)	ADCETRIS* Seattle Genetics CD30 ADC R/R sALCL (CN) ADCETRIS Seattle Genetics CD30 ADC R/R HL (CN) ADCETRIS* ALK inhibitor 2L ALK+NSCLC (JP, CN) Cabozantinib Exelixis VEGFR/RTK inhibitor 2L RCC (JP) Cabozantinib Exelixis VEGFR/RTK inhibitor 2L HCC (JP) Niraparib Tesaro PARP 1/2 inhibitor Ovarian cancer – salvage (JP) Niraparib Tesaro PARP 1/2 inhibitor Ovarian cancer – salvage (JP) ICLUSIG* BCR-ABL inhibitor TKI res. chronic phase CML (US)	ADCETRIS* Seattle Genetics CD30 ADC 1L PTCL (EU, JP) ALUNBRIG* ALK inhibitor 1L ALK+NSCLC (EU, US) NINLARO* Proteasome inhibitor R/R Amyloidosis (GL) NINLARO* Proteasome inhibitor R/R MM triplet Tx (GL) NINLARO* Proteasome inhibitor R/R MM doublet Tx (US, EU, JP) NINLARO* Proteasome inhibitor R/R MM (GL) NINLARO* Proteasome inhibitor Maint. ND MM not SCT (GL) NINLARO* Proteasome inhibitor Maint. ND MM post-SCT (GL)	ADCETRIS* Seattle Genetics CD30 ADC FL HL (EU)
GASTRO-ENTEROLOGY		ENTYVIO* α4β7 mAb GVHD Prophylaxis Vonoprazan PCAB GERD PPI partial resp. (EU)	ALOFISEL* mesenchymal stem cells Perianal Fistulas in CD (US) Vonoprazan PCAB Acid-related diseases (CN) ENTYVIO* α4β7 mAb SubQ UC (US, EU, JP) GATTEX GLP-2R agonist Adult-SBS (JP) ENTYVIO* α4β7 mAb Ulcerative Colitis (CN) GATTEX GLP-2R agonist Pediatric-SBS (JP) ENTYVIO* α4β7 mAb adalimumab H2H (GL)	ENTYVIO* α4β7 mAb Crohn's Disease (JP) GATTEX GLP-2R agonist Pediatric-SBS (US)
NEUROSCIENCE			BUCCOLAM GABA Allosteric Modulator Seizures (JP) MYDAYIS Mixed Amphetamine salts XR ADHD pediatric (US)	TRINTELLIX™ Lundbeck Multimodal anti-depressant MDD (JP) VYVANSE Shionogi Amphetamine-based psychostimulant ADHD (JP)
RARE DISEASES			OBIZUR Ipsen FVIII replacement CHAWI Surgery ADYNOVATE Pediatric Hema (EU) VONVENDI vWF replacement vWD Prophylaxis VONVENDI vWF replacement vWD Pediatric	TAKHZYRO Anit-kallikrein mAb HAE prophylaxis (CN)
PLASMA-DERIVED THERAPIES		<div style="border: 1px solid black; padding: 5px;"> <p> Orphan Drug Designation (in any region / indication for a given asset)</p> <p> Stage-ups/additions after Q2 FY18</p> <p> Stage-ups/additions since April 1, 2018</p> <p> Registration enabling</p> </div>	CINRYZE C1-inh SC HAE prophylaxis HYQVIA Haloxyme IgG+ rh-hyaluronidase Pediatric PID CINRYZE C1-inh HAE prophylaxis (JP) HYQVIA Haloxyme IgG+ rh-hyaluronidase CIDP CINRYZE C1-inh AMR	